GSK shareholders to vote on Novartis megadeal in December

Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline ($GSK) and Novartis ($NVS) worth more than $20 billion. The British pharma giant has asked its investors to vote at a Dec. 18 meeting on the proposed deal, which will send GSK's oncology drugs to Switzerland and most of Novartis' flu business to Glaxo, as well as establish a consumer healthcare JV. "This is the most significant transaction for the company since the creation of GlaxoSmithKline in 2000," GSK chairman Christopher Gent wrote in a shareholder letter seen by ReutersNews | More

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.